Aradigm Corporation (NASDAQ:ARDM)‘s stock had its “buy” rating reaffirmed by research analysts at Ladenburg Thalmann Financial Services in a report released on Monday. They presently have a $10.00 target price on the stock, up from their prior target price of $7.50. Ladenburg Thalmann Financial Services’ price target indicates a potential upside of 295.26% from the stock’s current price.

Separately, Zacks Investment Research upgraded shares of Aradigm Corporation from a “sell” rating to a “hold” rating in a report on Monday, June 5th.

Aradigm Corporation (NASDAQ:ARDM) traded up 32.41% on Monday, reaching $3.35. 5,447,206 shares of the company’s stock traded hands. Aradigm Corporation has a 52-week low of $0.78 and a 52-week high of $7.19. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.39. The firm’s market cap is $48.34 million.

Aradigm Corporation (NASDAQ:ARDM) last posted its quarterly earnings data on Thursday, August 10th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.37. Aradigm Corporation had a negative net margin of 196.65% and a negative return on equity of 665.03%. The company had revenue of $7.68 million for the quarter. On average, equities research analysts predict that Aradigm Corporation will post ($0.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Aradigm Corporation (ARDM) Receives “Buy” Rating from Ladenburg Thalmann Financial Services” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at

About Aradigm Corporation

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with's FREE daily email newsletter.